MORAVCOVÁ, Katarína, Martina KARBANOVÁ, Maxi Pia BRETSCHNEIDER, Markéta SOVOVÁ, Jaromir OZANA and Eliska SOVOVA. Comparing Digital Therapeutic Intervention with an Intensive Obesity Management Program: Randomized Controlled Trial. Nutrients. Basel: MDPI, 2022, vol. 14, No 10, p. 1-14. ISSN 2072-6643. Available from: https://dx.doi.org/10.3390/nu14102005.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Comparing Digital Therapeutic Intervention with an Intensive Obesity Management Program: Randomized Controlled Trial
Authors MORAVCOVÁ, Katarína (203 Czech Republic, guarantor), Martina KARBANOVÁ (203 Czech Republic, belonging to the institution), Maxi Pia BRETSCHNEIDER, Markéta SOVOVÁ (203 Czech Republic), Jaromir OZANA (203 Czech Republic) and Eliska SOVOVA (203 Czech Republic).
Edition Nutrients, Basel, MDPI, 2022, 2072-6643.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30308 Nutrition, Dietetics
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.900
RIV identification code RIV/00216224:14110/22:00125801
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/nu14102005
UT WoS 000801761100001
Keywords in English obesity; diabetes mellitus type 2; prevention; digital therapeutics; mobile application; randomized controlled trial; lifestyle intervention; metabolic syndrome; insulin resistance
Tags 14110525, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 25/1/2023 09:59.
Abstract
In this study, we evaluated whether the digital program Vitadio achieves comparable results to those of an intensive in-person lifestyle intervention in obesity management. This is a 12-month prospective, randomized controlled trial. Obese patients with insulin resistance, prediabetes or type 2 diabetes were included. The intervention group (IG) used Vitadio. The control group (CG) received a series of in-person consultations. Body weight and various metabolic parameters were observed and analyzed with ANOVA. The trial is ongoing and the presented findings are preliminary. Among 100 participants (29% men; mean age, 43 years; mean BMI, 40.1 kg/m2), 78 completed 3-month follow-up, and 51 have completed the 6-month follow-up so far. Participants significantly (p < 0.01) reduced body weight at 3 months (IG: −5.9 ± 5.0%; CG: −4.2 ± 5.0%) and 6 months (IG: −6.6±6.1%; CG: −7.1 ± 7.1%), and the difference between groups was not significant. The IG achieved favorable change in body composition; significant improvement in TAG (−0.6 ± 0.9 mmol/l, p < 0.01), HDL (0.1 ± 0.1%, p < 0.05), HbA1c (−0.2 ± 0.5%, p < 0.05) and FG (−0.5 ± 1.5 mmol/l, p < 0.05); and a superior (p = 0.02) HOMA-IR reduction (−2.5 ± 5.2, p < 0.01). The digital intervention achieved comparable results to those of the intensive obesity management program. The results suggest that Vitadio is an effective tool for supporting patients in obesity management and diabetes prevention.
PrintDisplayed: 1/6/2024 13:01